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Abstract
Summary The associations of volumetric and areal bone
mineral density (BMD) measures with incident cardiovas-
cular disease (CVD) were studied in a biracial cohort of
2,310 older adults. BMD measures were inversely related to
CVD in women and white men, independent of age and
shared risk factors for osteoporosis and CVD.
Introduction We investigated the associations of volumetric
(vBMD) and areal (aBMD) bone mineral density measures
with incident cardiovascular disease (CVD) in older adults
enrolled in the Health, Aging, and Body Composition study.
Methods The incidence of CVD was ascertained in 2,310
well-functioning white and black participants (42% black;
55% women), aged 68–80 years. aBMD measures of the
hip were assessed using DXA. Spine trabecular, integral,
and cortical vBMD measures were obtained using QCT.
Results During an average follow-up of 5.4 years, 23% of
men and 14% of women had incident CVD. Spine vBMD
measures were inversely associated with incident CVD in
white men [HR(integral)=1.39, 95% CI 1.03–1.87; HR
(cortical)=1.38, 95% CI 1.03–1.84], but not in black men.
In women, aBMD measures of the total hip (HR=1.36, 95%
CI 1.03–1.78), femoral neck (HR=1.44, 95% CI 1.10–1.90),
and trochanter (HR=1.34, 95% CI 1.04–1.72) exhibited
significant associations with CVD in blacks, but not in
whites. All associations were independent of age and shared
risk factors between osteoporosis and CVD, and were not
explained by inflammatory cytokines or oxidized LDL.
Conclusion Our results provide support for an inverse
association between BMD and incident CVD. Further
research should elucidate possible pathophysiological
mechanisms linking osteoporosis and CVD.
Keywords Areal BMD . Incident cardiovascular disease .
Inflammatory cytokines . Oxidized LDL . Volumetric BMD
Introduction
Cardiovascular disease (CVD) and osteoporosis are com-
mon age-related conditions. Mounting biological [1–5]
and epidemiological evidence suggests a possible link
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between the two diseases. In both cross-sectional and
longitudinal epidemiologic studies, low bone mass has
been related to increased cardiovascular mortality [6–10],
cardiovascular morbidity [11–18], and subclinical mea-
sures of atherosclerosis [19–27].
Osteoporosis was found to be a strong predictor of future
cardiovascular outcomes in postmenopausal women with
low bone mass, independent of age and other traditional
cardiovascular risk factors (adjusted HR=3.9, 95% CI 2.0–
7.7) [12]. It was also associated with angiographically-
determined coronary artery disease in a retrospective
analysis of a population predominantly of women referred
for angiography and BMD assessment [13]. Lower bone
mass was related to higher incident coronary heart disease
[15], incident stroke [17], and prevalent stroke in white
postmenopausal women [16]. Associations between BMD
and CVD were also reported in men. Previous myocardial
infarction was associated with low BMD in a multiethnic
population of men in the Third National Health and Nutrition
Examination Survey (NHANES III) [14]. Lower bone
mineral content was related to asymmetrical symptomatic
peripheral arterial disease in a small study involving 18 men
[18]. Recently, in a cross-sectional analysis in the Health,
Aging, and Body Composition (Health ABC) study, we
observed that volumetric BMD (vBMD) measures of the
spine were significantly associated with prevalent CVD in
women and men, and areal BMD (aBMD) of the trochanter
was related to prevalent CVD in women. These inverse
relationships were not age-related and were independent of
shared risk factors between osteoporosis and CVD [11].
Although several lines of evidence support a link
between CVD and osteoporosis, the nature of this associ-
ation and the mechanisms involved are still not clearly
elucidated. Most of the earlier work focused on white
women [6–8, 12, 13, 17, 20, 21, 23]. Less is known about
the presence of this relationship in men and in black
populations. Additionally, previous studies relied on prev-
alent CVD or subclinical markers of atherosclerosis [13, 14,
16, 18–24, 26, 27], and areal assessments of BMD [6–10,
12–19, 21–27]. To our knowledge, no study assessed the
association of volumetric BMD measures with incident
CVD events. Furthermore, while inflammatory cytokines
and oxidized LDL (oxLDL) were suggested as common
denominators in the association between osteoporosis and
CVD, their role requires further investigation.
The purpose of this analysis was to longitudinally
examine the association of baseline volumetric and areal
BMD measures with incident CVD in a biracial cohort
of men and women with no history of CVD; and to
determine whether such associations were a) independent
of age, b) independent of shared risk factors between
osteoporosis and CVD, or c) explained by common
pathophysiological factors such as oxLDL or the inflamma-




Participants were enrolled in the Health, Aging, and Body
Composition (Health ABC) study, a population-based
prospective study investigating the association between
changes in body composition and functional decline in the
elderly. The cohort included 3075 well-functioning, com-
munity-dwelling men and women aged 68–80 years. The
demographic distribution of the population was as follows:
729 black women, 855 white women, 552 black men, and
939 white men. Participants were recruited between April
1997 and June 1998 and were identified from a random
sample of white Medicare beneficiaries and all age-eligible
black community residents in designated zip code areas
surrounding Pittsburgh, PA, and Memphis, TN. Subjects
who reported difficulty walking one quarter of a mile,
climbing 10 steps, or performing basic activities of daily
living, who had a life threatening illness in the 3 years prior
to the study, or who were planning to move in the next
3 years were excluded. Written informed consent was
obtained from all participants. The study protocol was
approved by the Institutional Review Boards of the
University of Pittsburgh and the University of Tennessee.
The current analyses included 2310 participants. We
excluded participants who had one or more cardiovascular
diseases (N=765) at the baseline visit including coronary
heart disease (CHD) (N=559), cerebrovascular disease
(N=223), or peripheral arterial disease (PAD) (N=158).
Areal BMD data was missing for 25 participants. Volumetric
BMD was collected at the Pittsburgh site only and was
therefore available for 1,095 participants (out of 1,124).
Incident cardiovascular disease
Incident CVD was defined as the onset of one or more of
the following conditions between study entry and June 30,
2004: coronary heart disease (CHD) (defined as coronary
death or any overnight hospitalization in an acute care
hospital due to myocardial infarction, angina pectoris,
symptomatic coronary insufficiency, or other ischemic heart
disease, N=277); cerebrovascular disease (defined as
cerebrovascular death or any overnight hospitalization due
to stroke or transient ischemic attacks, N=150), PAD
(defined as overnight hospitalization due to lower extremity
claudication, atherosclerosis, or thrombosis/ embolism,
N=32), or carotid artery disease (defined by vascular or
surgical procedure to improve flow to the ipsilateral brain,
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symptomatic disease with abnormal findings (>50% stenosis
on carotid angiogram or Doppler), or symptomatic disease
with carotid artery disease listed on discharge summary,
N=33).
Participants were contacted every 6 months, alternating
clinic visits and telephone interviews, to elicit information
about events. For each reported event, hospital records were
collected and abstracted. Cardiovascular events were
reviewed locally by a study physician, and verified using
standard criteria. Dates and causes of death were verified by
a committee made up of 4–6 Health ABC physicians, using
death certificates, hospital records, and proxy interviews.
Adjudicated events occurring through June 30, 2004 were
available. Follow-up time was calculated from the date of the
first study visit to the date of the first cardiovascular event, or
last contact with the patient (for participants who did not
develop CVD or were lost to follow-up), or death (for
participants who died from non-CVD causes). The average
follow-up time was 5.4 years (range of follow-up=0.02–
7.17 years, median=6.02 years).
Areal bone mineral density (aBMD)
Baseline areal BMD (g/cm2) measures of the total hip and
hip subregions (femoral neck and trochanter) were deter-
mined using dual-energy X-ray absorptiometry (DXA)
(Hologic 4500A, version 9.03; Hologic, Inc., Waltham,
MA, USA). DXA quality assurance measures were per-
formed at both study sites and identical scan protocols were
used for all participants.
Volumetric bone mineral density (vBMD)
Baseline volumetric BMD measures (mg/cc) of the spine
were determined using quantitative computed tomography
(QCT) (General Electric 9800 Advantage, 80 kVp/
140 mAs, 10-mm slice thickness; GE Medical Systems,
Milwaukee, WI). QCT images were acquired at the level of
the L3 vertebra to obtain trabecular and integral BMD.
Cortical BMD, which includes the cortical shell of the
vertebral body and the posterior elements, was estimated by
taking the difference in BMC between the integral and
trabecular regions and dividing it by the difference in the
volumes of these two regions. Scans were performed by
certified technicians and analyzed with a standardized
protocol at the University of California, San Francisco.
Inflammatory markers and oxidized LDL
The concentrations of IL-6, TNF-α, and oxLDL were
obtained from frozen stored serum samples collected via
venipuncture after an overnight fast at baseline. IL-6 and
TNF-α were measured in duplicate using commercial
ELISA assays from R&D Systems (Minneapolis, MN).
The lower detectable limit was 0.10 pg/ml for IL-6 and
0.18 pg/ml for TNF-α, the detection range was 0.156–
17.0 pg/ml for IL-6 and 0.5–32 pg/ml for TNF-α, and the
interassay coefficient of variation was 10.3% for IL-6 and
15.8% for TNF-α. Plasma levels of oxLDL were measured
using a monoclonal antibody (4E6)-based competition
enzyme-linked immunosorbent assay. The interassay coef-
ficient of variation of oxLDL is 12%. IL-6, TNF-α, and
oxLDL were available for 2,197, 2,152, and 2,282
participants, respectively.
Potential confounders
Sociodemographic factors (age, gender, race, study site,
education), smoking history, alcohol consumption, weekly
physical activity from walking and exercise (Kcal/Kg/
hour), medication use (including hormone therapy, statins,
osteoporosis drugs, thiazide diuretics, systemic cortico-
steroids, calcium supplements, vitamin D supplements),
and time since menopause were determined by an inter-
view-administered questionnaire. Medication use in the
previous 2 weeks was coded using the Iowa Drug
Information System (IDIS) ingredient codes [28].
Lower extremity physical function was assessed by the
Health ABC performance battery, a supplemented version
of the lower-extremity performance test used in the
Established Populations for the Epidemiologic Studies of
the Elderly (EPESE; chair stands, standing balance, 6-m
walk for gait speed) with increased test duration, a single
foot stand, and a narrow walk test of balance as previously
described (score range 0–12) [29]. Height and weight were
obtained using a Harpenden stadiometer (Holtain, Wales,
UK) and a standard balance beam, respectively. Body mass
index (BMI) was calculated as weight divided by height
squared (Kg/m2). Seated systolic and diastolic blood
pressures were measured by a manual mercury sphygmo-
manometer using a standardized protocol.
Prevalent diabetes was defined as self-report of diabetes
previously diagnosed by a physician, use of hypoglycemic
medications, or a fasting glucose ≥126 mg/dl. Prevalent
hypertension was defined as self-report of hypertension and
use of anti-hypertensive medications. Prevalent osteoporosis
(total hip BMD 2.5 SD or more below the young adult
mean) and low bone mass (total hip BMD between 1.0 and
2.5 SD below the young adult mean) were defined using
gender and race-specific T-scores determined from the
NHANES III study population [30].
Total cholesterol, high-density lipoprotein (HDL) cho-
lesterol, and triglyceride were measured by a colorimetric
technique (Johnson & Johnson Vitros 950 analyzer, New
Brunswick, New Jersey). Low-density lipoprotein (LDL)
cholesterol was calculated using the Friedewald equation.
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Plasma glucose was measured using an automated glucose
oxidase reaction (YSI 2300 STAT Plus Glucose & Lactate
Analyzer; YSI Life Sciences, Inc., Yellow Springs, Ohio).
Serum insulin was assessed using a commercially available
radioimmunoassay kit (Pharmacia, Uppsala, Sweden).
Data analysis
All analyses were stratified by gender. Baseline character-
istics and BMD measures of groups with or without
incident CVD were compared using chi-square test for
categorical variables and either 2-sample t-test or Wilcoxon
rank-sum test for continuous data. Cox proportional hazards
regression was used to estimate the hazard ratio (HR) of
incident CVD per SD decrease in BMD (calculated as the
deviation from the mean BMD divided by the standard
deviation of the BMD measure in each gender). Unadjust-
ed, age-adjusted, and risk factors adjusted models were
fitted. Variables were selected for entry into the multiple
Cox models if they were associated with incident CVD and
any of the BMD variables at the 0.15 level of significance
in univariate analyses. Separate regression models were
fitted for each BMD variable. The proportional hazards
assumption was checked by testing the significance of
interaction terms of BMD variables with time. Racial
differences in the relationship of BMD with incident CVD
were tested by entering product terms for race and BMD
measures in the adjusted Cox regression models. In cases
where significant race interactions were observed at the 0.1
level of significance, the analyses were further stratified by
race. In women, interactions between race and aBMD
measures of the total hip (p-value for BMD x race=0.05),
femoral neck (p-value=0.04), and trochanter (p-value=0.05)
were observed. In men, interactions between race and
integral (p-value=0.07), cortical (p-value=0.08), and trabec-
ular (p-value=0.10) vBMD measures of the spine were
observed. Therefore, the Cox models specific for these BMD
measures were further stratified by race.
The effects of IL-6, TNF-α, and oxLDL on statistically
significant associations between BMD measures and CVD
were tested by introducing these variables, separately, into
adjusted Cox models. Because of the skewed distribution of
IL-6, TNF-α, and oxLDL, their log-transformed values
were used in analyses. Data were analyzed using SAS
version 8.01 (SAS Institute Inc., Cary, NC, USA).
Results
Participants characteristics
During an average follow-up of 5.4 years, 23% (241 out of
1040) of men and 14% (182 out of 1270) of women had an
incident CVD event. Compared to men who did not
develop CVD, those who did were older, less educated,
more likely to have diabetes, had lower HDL and Health
ABC physical performance score, and had higher levels of
glucose, systolic blood pressure, and inflammatory markers.
In women, participants who had incident CVD were more
likely to be hypertensive or diabetic, had higher BMI,
glucose level, systolic blood pressure, and inflammatory
markers, had a lower Health ABC physical performance
score, and were less likely to be calcium users (Table 1).
BMD and incident CVD in women
In women, none of the areal or volumetric BMD variables
were significantly associated with incident CVD in unad-
justed or age-adjusted analyses. However, after controlling
for shared risk factors between CVD and BMD, femoral
neck aBMD was found to be significantly associated with
CVD. A decrease in femoral neck aBMD by 1 SD below
the mean was related to a 24% increased risk for incident
CVD (Table 2).
In race-specific adjusted models, we observed that
aBMD measures of the total hip and hip subregions were
significantly associated with CVD in black women. A 1 SD
decrease in aBMD of the total hip, femoral neck, and
trochanter was related to an increased CVD risk in the order
of 36%, 44%, and 34%, respectively. On the other hand,
none of these measures showed associations with CVD in
white women (Table 3).
We looked at the effects of IL-6, TNF-α, and oxLDL on
the associations of BMD with CVD in black women. IL-6
level was significantly higher among black women who
had CVD (median IL-6=1.97 pg/ml) compared to those
who did not (median IL-6=1.82 pg/ml, p=0.003). Howev-
er, IL-6 was positively correlated with aBMD measures of
the hip (total hip: r=0.17, p<.0001; femoral neck: r=0.19,
p<.0001; trochanter: r=0.14, p=.0009). Adding IL-6 to the
adjusted models did not affect the strength or significance
of the association between BMD measures and CVD
(Table 4). For instance, the adjusted HR for incident CVD
per 1 SD decrease in femoral neck aBMD was similar
before (HR=1.51, 95% CI 1.14–1.99) and after adjusting
for IL-6 (HR=1.49, 95% CI 1.13–1.96). Similarly, adjust-
ing for TNF-α or oxLDL had no effect on the associations
of aBMD measures with incident CVD (Table 4).
BMD and incident CVD in men
In men, none of the BMD measures showed statistically
significant associations with CVD in unadjusted or adjusted
analyses. However, there was a trend for higher CVD
incidence with decreased integral (HR=1.17, 95% CI 0.93–
1.48), cortical (HR=1.18, 95% CI 0.94–1.48), and trabec-
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Table 1 Comparison of baseline characteristics (%, mean ± SD, or median (IQR)) in women and men by incident cardiovascular disease status,















Age (yrs) 73.4±2.8 73.3±2.8 .68 73.4±2.8 74.1±3.1 .001
% Black 43.4 50.0 .10 40.0 34.4 .12
% Post-secondary education 38.8 35.4 .61 48.1 38.9 .04
Lifestyle/Diet
% Smoking 8.6 11.0 .27 11.4 11.2 .95
% Alcohol drinking 43.8 40.1 .35 58.9 55.4 .34
Physical activity (Kcal/week)* 365.8 (47.2–959.7) 215.1 (18.5–938.1) .06 635.8 (170.6–1737.5) 701.1 (129.1–1969.1) .98
Calcium supplements 31.6 24.2 .04 8.8 6.7 .30
Vitamin D supplement 14.9 11.0 .16 4.1 2.5 .24
Anthropometric Measures
BMI (kg/ms) 27.5±5.6 28.6±5.3 .02 27.0±4.0 27.2±4.0 .36
Weight (Kg) 70.2±15.0 72.2±13.4 .08 81.5±13.5 82.0±13.3 .62
Height (cm) 159.6±6.1 159.1±6.3 .29 173.7±6.7 173.4±6.2 .54
HABC performance score 6.8±1.6 6.5±1.6 .03 7.6±1.6 7.2±1.7 .0004
Lipids
Total cholesterol (mg/dl) 213.0±37.4 217.2±39.9 .16 192.9±35.4 196.2±31.4 .18
LDL (mg/dl) 124.9±35.7 128.8±38.7 .21 118.5±32.7 122.7±28.9 .06
HDL (mg/dl) 61.0±16.8 60.3±18.9 .62 48.9±14.8 46.3±12.8 .01
Triglyceride (mg/dl)* 118.5 (90.0–162.5) 127.0 (92.0–166.0) .17 112.0 (83.0–151.0) 119.0 (89.0–165.0) .11
Inflammatory Markers and oxLDL
IL-6 (pg/ml)* 1.7 (1.1–2.5) 2.2 (1.3–3.2) <.0001 1.7 (1.2–2.5) 2.0 (1.4–3.0) .0004
TNF-α (pg/ml)* 3.0 (2.3–3.8) 3.1 (2.6–4.3) .007 3.1 (2.4–3.9) 3.4 (2.6–4.3) .002
oxLDL (mg/dl) 1.1 (0.8–1.6) 1.3 (0.9–1.7) .09 1.1 (0.8–1.5) 1.2 (0.9–1.6) .10
Blood pressure (mmHg)
Systolic 135.3±20.4 138.6±21.2 .04 134.5±19.9 137.7±21.5 .03
Diastolic 70.0±11.6 71.2±11.7 .19 73.3±11.4 73.8±11.5 .56
Glucose level (mg/dl)* 91.0 (85.0–101.0) 94.0 (87.0–104.0) .007 95.0 (90.0–120.0) 97.0 (90.0–119.5) .004
Insulin level (uIU/ml)* 6.8 (4.8–10.0) 7.6 (5.0–10.8) .05 6.6 (4.8–10.0) 7.0 (4.8–10.0) .49
Time since menopause (yrs) 27.4±7.4 27.9±8.8 .46 – – –
Medical history
% Hypertension 43.3 53.8 .008 31.3 36.7 .12
% Diabetes 12.8 23.3 .0002 18.2 28.8 .0004
% Osteoporosis 14.0 15.5 .61 3.0 4.6 .23
Medication use
% Oral estrogen 23.9 22.0 .56
% Osteoporosis drugs 8.3 7.1 .59 0.6 0.8 .73 a
% Statins 10.9 13.7 .26 7.2 5.4 .35
% Thiazide 21.3 30.2 .008 12.7 15.9 .20
% Oral steroid 2.8 5.0 .12 1.2 0.8 .74 a
% Diabetes drugs 8.9 15.9 .003 10.5 17.6 .004
BMD measures
Volumetric (mg/cc)
Spine integral 237.6±51.5 241.5±49.2 .49 265.6±56.5 254.3±54.9 .07
Spine trabecular 110.9±41.2 114.1±36.6 .48 134.9±43.9 128.4±45.7 .19
Spine cortical 277.9±54.3 280.6±51.7 .65 311.5±59.8 299.2±58.2 .06
Areal (g/cm2)
Total hip 0.81±0.15 0.81±0.14 .84 0.97±0.15 0.96±0.16 .40
Trochanter 0.62±0.12 0.61±0.11 .81 0.76±0.14 0.75±0.14 .30
Femoral neck 0.70±0.13 0.69±0.12 .76 0.80±0.14 0.79±0.14 .43
*P-value obtained using Wilcoxon rank-sum test since variables were not normally distributed
a Fisher’s exact test
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ular (HR=1.10, 95% CI 0.87–1.39) vBMD measures of the
spine (Table 2).
In adjusted models stratified by race, we observed that
spine integral and cortical vBMD measures were signifi-
cantly associated with CVD in white men. The risk of
incident CVD was increased by 39% and 38%, respectively,
with every SD decrease in integral and cortical vBMD
measures. On the other hand, none of these measures
showed associations with CVD in black men (Table 3).
We looked at the effects of IL-6, TNF-α, and oxLDL on
the associations of BMD with CVD in white men. White
men with CVD had higher IL-6 and TNF-α levels than
those who did not have CVD, whereas no significant
difference in oxLDL was observed between the two groups.
IL-6, TNF-α, and oxLDL were not correlated with integral
or cortical BMD measures in white men, and adding them,
separately, to adjusted Cox models did not affect the
associations of BMD with CVD (Table 5).
Discussion
This prospective analysis examined the association of BMD
measures with incident CVD in a biracial cohort of older
Table 2 Results of Cox regression models for incident CVD: unadjusted, age-adjusted, and risk factors-adjusted hazard ratios (95% CI) per 1 SD
decrease in baseline BMD measures for women and men in the Health ABC study
Women1 Men2









Unadjusted 1257 (181) 0.98 (0.85–1.14) 1028 (237) 1.06 (0.93–1.20)
Adjusted for age 1257 (181) 0.99 (0.85–1.14) 1028 (237) 1.04 (0.91–1.18)
Adjusted for shared risk factors
between osteoporosis and CVD
1208 (176) 1.18 (0.97–1.43) 976 (217) 1.04 (0.89–1.22)
Femoral neck aBMD
Unadjusted 1257 (181) 1.02 (0.88–1.18) 1028 (237) 1.05 (0.92–1.19)
Adjusted for age 1257 (181) 1.02 (0.88–1.18) 1028 (237) 1.02 (0.90–1.16)
Adjusted for shared risk factors
between osteoporosis and CVD
1208 (176) 1.24 (1.02–1.52) a 976 (217) 1.04 (0.89–1.21)
Trochanter aBMD
Unadjusted 1257 (181) 1.01 (0.88–1.17) 1028 (237) 1.08 (0.94–1.22)
Adjusted for age 1257 (181) 1.02 (0.88–1.18) 1028 (237) 1.06 (0.93–1.20)
Adjusted for shared risk factors
between osteoporosis and CVD
1208 (176) 1.16 (0.97–1.39) 976 (217) 1.07 (0.92–1.25)
Spine integral vBMD
Unadjusted 599 (94) 0.92 (0.76–1.13) 496 (103) 1.20 (0.98–1.47)
Adjusted for age 599 (94) 0.94 (0.76–1.15) 496 (103) 1.18 (0.96–1.44)
Adjusted for shared risk factors
between osteoporosis and CVD
574 (93) 1.02 (0.80–1.28) 475 (95) 1.17 (0.93–1.48)
Spine trabecular vBMD
Unadjusted 599 (94) 0.93 (0.76–1.13) 496 (103) 1.14 (0.93–1.40)
Adjusted for age 599 (94) 0.94 (0.77–1.15) 496 (103) 1.11 (0.91–1.37)
Adjusted for shared risk factors
between osteoporosis and CVD
574 (93) 0.99 (0.79–1.24) 475 (95) 1.10 (0.87–1.39)
Spine cortical vBMD
Unadjusted 599 (94) 0.95 (0.77–1.16) 496 (103) 1.20 (0.98–1.48)
Adjusted for age 599 (94) 0.96 (0.78–1.18) 496 (103) 1.19 (0.97–1.46)
Adjusted for shared risk factors
between osteoporosis and CVD
574 (93) 1.04 (0.83–1.31) 475 (95) 1.18 (0.94–1.48)
1Models in women were adjusted for: age, race, study site, physical activity, Health ABC physical performance score, BMI, cholesterol, systolic
blood pressure, glucose level, history of hypertension, and use of diabetes drugs, calcium supplements, and oral estrogen
2Models in men were adjusted for: age, race, study site, education, physical activity, Health ABC physical performance score, BMI, HDL, LDL,
systolic blood pressure, glucose level, history of hypertension, and use of diabetes drugs
3 BMD SDs: Women: total hip aBMD=0.15 g/cm2, trochanter aBMD=0.12 g/cm2, femoral neck aBMD=0.13 g/cm2, integral vBMD=51.14 mg/
cc, trabecular vBMD=40.53 mg/cc, cortical vBMD=53.87 mg/cc. Men: total hip aBMD=0.16 g/cm2, trochanter aBMD=0.14 g/cm2, femoral
neck aBMD=0.14 g/cm2, integral vBMD=56.3 mg/cc, trabecular vBMD=44.3 mg/cc, cortical BMD=59.7 mg/cc
a p<0.05
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men and women who had no evidence of cardiovascular
disease at baseline. Volumetric BMD measures of the spine
were significantly associated with incident CVD in white
men. Areal BMD of the femoral neck was related to CVD
in women, and in race-specific analyses, aBMD measures
of the total hip, trochanter, and femoral neck were
associated with CVD in black women. These inverse
relationships were independent of age and shared risk
factors between BMD and CVD and were not explained by
ox-LDL, IL-6, or TNF-α.
Our findings in men make an important addition to the
existing literature as this is the first longitudinal study to
report an association between BMD and cardiovascular
events in men with no history of CVD. These associations
were consistent with previous findings. In a cross-sectional
analysis in this cohort, we observed significant inverse
associations between spine vBMD measures and prevalent
CVD in men. A one SD decrease in cortical, integral, or
trabecular vBMD was associated with 36%, 34%, and 25%
increased odds for CVD, respectively [11]. In NHANES III,
men with a history of MI had a significantly higher
prevalence of low BMD (OR=1.39, 95% CI 1.03–1.87)
[14]. In a study involving 18 men with asymmetrical
symptomatic peripheral arterial disease, bone mineral
Table 3 Adjusted hazard ratios (95% CI) for incident CVD per 1 SD decrease in baseline BMD measures for black and white women and men in
the Health ABC Study
Black women1 White women1
BMD N at risk (events) Hazard ratio (95% CI) N at risk (events) Hazard ratio (95% CI)
Total hip aBMD 526 (86) 1.36 (1.03–1.78) a 682 (90) 1.02 (0.76–1.37)
Femoral neck aBMD 526 (86) 1.44 (1.10–1.90) b 682 (90) 1.05 (0.78–1.41)
Trochanter aBMD 526 (86) 1.34 (1.04–1.72) a 682 (90) 1.00 (0.77–1.32)
Black Men2 White Men2
Spine integral vBMD 187 (30) 0.86 (0.58–1.28) 288 (65) 1.39 (1.03–1.87) a
Spine trabecular vBMD 187 (30) 0.84 (0.57–1.24) 288 (65) 1.27 (0.94–1.72)
Spine cortical vBMD 187 (30) 0.87 (0.59–1.28) 288 (65) 1.38 (1.03–1.84) a
a p<0.05
b p<0.01
1Models in women were adjusted for the following: age, study site, physical activity, Health ABC physical performance score, BMI, cholesterol,
systolic blood pressure, glucose level, history of hypertension, and use of diabetes drugs, calcium supplements, and oral estrogen
2Models in men were adjusted for the following: age, race, study site, education, physical activity, Health ABC physical performance score, BMI,
HDL, LDL, systolic blood pressure, glucose level, history of hypertension, and use of diabetes drugs
Table 4 Effect of controlling for IL-6, TNF-α, or oxLDL on the
adjusted associations of aBMD measures with incident CVD in black
women






factors + IL-6, TNF-α,
or oxLDL2 Hazard ratio
(95% CI)
Total hip aBMD
IL-6 502 (84) 1.39 (1.06–1.83) a 1.39 (1.06–1.82) a
TNF-α 486 (77) 1.32 (0.99–1.76) 1.33 (1.00–1.77)
oxLDL 524 (86) 1.32 (1.02–1.72) a 1.35 (1.03–1.77) a
Femoral neck aBMD
IL-6 502 (84) 1.51 (1.14–1.99) b 1.49 (1.13–1.96) b
TNF-α 486 (77) 1.46 (1.09–1.96) a 1.48 (1.10–1.98) b
oxLDL 524 (86) 1.42 (1.09–1.86) b 1.44 (1.09–1.89) b
Trochanter aBMD
IL-6 502 (84) 1.36 (1.05–1.77) a 1.35 (1.05–1.74) a
TNF-α 486 (77) 1.32 (1.01–1.73) a 1.31 (1.01–1.72) a
oxLDL 524 (86) 1.32 (1.02–1.69) a 1.34 (1.03–1.72) a
a p<0.05
b p≤0.01
1 Adjusted for same risk factors listed in Tables 2 and 3
2 oxLDL models did not include cholesterol level due to the high
correlation between the two measures
Table 5 Effect of controlling for IL-6, TNF-α, or oxLDL on the
adjusted associations of vBMD measures with incident in white men











IL-6 280 (62) 1.37 (1.01–1.86) a 1.38 (1.02–1.88) a
TNF-α 276 (63) 1.40 (1.04–1.89) a 1.40 (1.04–1.89) a
oxLDL 292 (66) 1.39 (1.04–1.87) a 1.41 (1.05–1.89) a
Cortical vBMD
IL-6 280 (62) 1.37 (1.02–1.85) a 1.38 (1.02–1.86) a
TNF-α 276 (63) 1.39 (1.03–1.86) a 1.38 (1.03–1.85) a
oxLDL 292 (66) 1.39 (1.04–1.85) a 1.41 (1.05–1.88) a
a p<0.05
b p<0.01
1 Adjusted for same risk factors listed in Tables 2 and 3
2 oxLDL models did not include LDL level due to the high correlation
between the two measures
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content was shown to be significantly lower in the affected
compared to the unaffected leg [18]. Additionally, BMD
was inversely related to CVD mortality in white men in the
NHANES I study and in a British population [9, 10].
Interestingly, the associations of BMD measures with
CVD were observed in white men, but not in blacks. This
might be explained by the lower BMD and the higher
incidence of CVD in white men compared to blacks. In this
cohort, the incidence of CVD was 23% in white men and
16% in black men. Spine vBMD measures were signifi-
cantly lower in whites than blacks (mean integral vBMD=
248.6 mg/cc in whites vs. 285.2 mg/cc in blacks, p<.0001;
mean cortical vBMD=294.8 mg/cc in whites vs 330.0 mg/cc
in blacks, p<.0001). Also, due to the smaller sample size
available for analysis in black men, we had limited power to
detect associations similar to those observed in whites.
In women, we observed that a decrease in femoral neck
aBMD by 1 SD below the mean was related to a 24%
increased risk for incident CVD. Notably, this association
was observed only after adjusting for risk factors and it
seemed to be masked by negative confounders such as BMI
and glucose level, which were associated with higher BMD
and increased risk for cardiovascular disease. In race-
specific analyses, lower aBMD measures of the total hip,
femoral neck, and trochanter were associated with higher
CVD risk in black women, but not in white women. To our
knowledge, none of the previous reports have explored
associations between BMD and CVD in black women
separately. Studies have focused on white women [6–8, 12,
13, 17, 20, 21, 23], and blacks have been excluded from
analyses due to their reduced risk for osteoporosis and
fractures [6, 7, 17]. A higher than expected prevalence of
low BMD was observed among black women in our cohort:
13% were osteoporotic, and 44.5% had low bone mass.
Estimates from NHANES III indicate that the prevalence of
osteoporosis and osteopenia in black women aged 50 years
and older are 8% and 28%, respectively [31]. The high
prevalence of osteoporosis and low bone mass in this group
of black women may have lead to more pronounced
associations between BMD and CVD.
Unlike other cross-sectional and longitudinal studies, we
did not observe an association between BMD and incident
CVD in white women. In the Multiple Outcomes of
Raloxifene Evaluation (MORE) trial, osteoporosis was
found to be a strong predictor of future cardiovascular
outcomes in postmenopausal women with low bone mass,
independent of age and other traditional cardiovascular risk
factors (adjusted HR=3.9, 95% CI 2.0–7.7) [12]. In the
MORE study, 53% of the women were osteoporotic and the
remaining 47% had low bone mass. In another study of
white postmenopausal women, the presence of aortic
calcification (AC) was associated with lower BMD and
higher prevalence of vertebral and hip fractures. The
progression of AC was also linked to increased trabecular
BMD loss at the spine. In this study, 70% of the women
had osteoporosis [20]. In our cohort, the prevalence of
osteoporosis in white women was 15%, consistent with
estimates from NHANES III [31]. However, the incidence
of CHD (15/1,000 person-years) was lower than that
reported in the Cardiovascular Health Study (CHS) for
white women of similar age (18.6/1,000 person-years) [32].
This suggests that the relationship between BMD and CVD
may be more evident in populations at high risk.
The lack of association of BMD with CVD in white
women may also be explained, in part, by selective survival
bias. We observed that white women who died from non-
CVD causes had lower baseline aBMD of the total hip,
compared to the rest of the group (mean aBMD=0.77 vs.
0.72, respectively, p-value=.03). This suggests that white
women with low BMD were at higher risk of death from
non-CVD causes, and were therefore eliminated from the
CVD risk group.
Traditionally, osteoporosis and CVD have been regarded
as independent processes that occur with aging. However,
mounting biological observations and epidemiological
evidence from this study and others suggest a link between
the two conditions that is independent of age. Several
hypotheses have been proposed to explain the link between
CVD and osteoporosis including shared etiological factors
(such as menopause, smoking, physical inactivity, etc.)
which may simultaneously promote atherosclerosis and
bone demineralization. In our analysis, the observed inverse
associations between BMD and incident CVD were present
after controlling for age and other common etiological
factors for osteoporosis and CVD including weight,
physical activity, blood pressure, and lipids. Common
pathophysiological mechanisms involving inflammatory
cytokines and oxidized lipids have been implicated in the
link between osteoporosis and CVD. Aging is associated
with increased levels of circulating inflammatory markers
such as IL-6 and TNF-α [33]. IL-6 was shown to stimulate
osteoclasts, thereby increasing the rates of bone remodeling
and bone loss [34]. Previous analyses in the Health ABC
cohort have shown that IL-6 and TNF-α were significantly
associated with prevalent clinical and subclinical disease
[35], as well as incident cardiovascular events [36]. The
role of oxidized lipids in atherogenesis is well established
[37]. In vitro, Parhami et al. observed that lipid oxidation
products including minimally oxidized LDL have opposite
effects on bone and vascular cells; they were found to
inhibit osteoblast differentiation in bone cells and stimulate
it in calcifying vascular cells [38]. In our analysis, oxLDL
and the inflammatory markers IL-6 and TNF-α did not
explain the associations of BMD measures with CVD. It is
possible that other cytokines are involved. The osteoprote-
gerin (OPG)/ receptor activator of nuclear factor kappa B
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(NF-κB) (RANK)/RANK ligand (RANKL) triad seems to
play a role in bone physiology and vascular calcification
[39]. Other mechanisms involving elevated homocysteine
levels [40], low endogenous sex hormones, imbalances in
the calciferol endocrine system [41], vitamin K status [42],
and genetic factors [39, 43] may also have a role in the link
between low BMD and CVD. Additionally, it has been
suggested that atherosclerosis, by reducing blood flow to
the lower extremities, could alter bone metabolism in the
hip and result in decreased bone density [18, 44].
Our study extends previous findings by longitudinally
examining the association of BMD with CVD in a healthy
cohort with no history of CVD, in separate gender and race
groups, and across a wider range of BMD values, not just the
lower range. This study also had the benefit of utilizing QCT
for volumetric determination of BMD at the spine. This
technique adjusts for differences in bone size, an important
confounder in studies that involve multiethnic groups and
different genders. The additional advantage of QCT is that, in
contrast to DXA, it is not affected by the presence of extra-
osseous calcification such as aortic calcification and degenar-
ative osteoarthritic changes, which get incorporated in the
region of interest and lead to a falsely increased areal bone
density of the spine. The main limitation of this study is the
generalizability of its findings to other populations because of
its inclusion of a well-functioning cohort of older adults.
Another limitation is that inflammatory cytokines were
measured at a single time point. Owing to their circadian
variability, more than one assay may be needed to adequately
classify an individual’s level.
In summary, we observed a longitudinal inverse associ-
ation between BMD measures and incident CVD in older
women and white men with no prior history of cardiovas-
cular disease. These findings provide further support for a
relationship between osteoporosis and CVD that is inde-
pendent of age and shared risk factors. Further research
should assess this association in separate race groups and
investigate common pathophysiological mechanisms be-
tween the two conditions. Once confirmed, a link between
low BMD and CVD may lead to the early identification of
subjects at higher risk for CVD, and to the potential for
common preventive and therapeutic interventions that target
both osteoporosis and CVD.
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